NCT02558140View on ClinicalTrials.gov

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 11, 2015

Primary Completion Date

November 6, 2017

Study Completion Date

November 6, 2017

Conditions
Neoplasms
Interventions
BIOLOGICAL

RO6874813

RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.

BIOLOGICAL

RO6874813

RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.

Trial Locations (4)

28050

START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid

37203

SCRI, Nashville

69373

Centre Leon Berard; Departement Oncologie Medicale, Lyon

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02558140 - A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter